Update on AUA guideline on the management of benign prostatic hyperplasia

Kevin T. McVary, Claus Roehrborn, Andrew L. Avins, Michael J. Barry, Reginald C. Bruskewitz, Robert F. Donnell, Harris E. Foster, Chris M. Gonzalez, Steven A. Kaplan, David F. Penson, James C. Ulchaker, John T. Wei

Research output: Contribution to journalArticlepeer-review

859 Scopus citations


Purpose: To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH). Materials and Methods: From MEDLINE® searches of English language publications (January 1999 through February 2008) using relevant MeSH terms, articles concerning the management of the index patient, a male <45 years of age who is consulting a healthcare provider for lower urinary tract symptoms (LUTS) were identified. Qualitative analysis of the evidence was performed. Selected studies were stratified by design, comparator, follow-up interval, and intensity of intervention, and meta-analyses (quantitative synthesis) of outcomes of randomized controlled trials were planned. Guideline statements were drafted by an appointed expert Panel based on the evidence. Results: The studies varied as to patient selection; randomization; blinding mechanism; run-in periods; patient demographics, comorbidities, prostate characteristics and symptoms; drug doses; other intervention characteristics; comparators; rigor and intervals of follow-up; trial duration and timing; suspected lack of applicability to current US practice; and techniques of outcomes measurement. These variations affected the quality of the evidence reviewed making formal meta-analysis impractical or futile. Instead, the Panel and extractors reviewed the data in a systematic fashion and without statistical rigor. Diagnosis and treatment algorithms were adopted from the 2005 International Consultation of Urologic Diseases. Guideline statements concerning pharmacotherapies, watchful waiting, surgical options and minimally invasive procedures were either updated or newly drafted, peer reviewed and approved by AUA Board of Directors. Conclusions: New pharmacotherapies and technologies have emerged which have impacted treatment algorithms. The management of LUTS/BPH continues to evolve.

Original languageEnglish (US)
Pages (from-to)1793-1803
Number of pages11
JournalJournal of Urology
Issue number5
StatePublished - May 2011


  • 5-alpha-reductase inhibitors
  • adrenergic alpha-antagonists
  • behavior therapy
  • prostatic hyperplasia
  • transurethral resection of prostate
  • urinary retention

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Update on AUA guideline on the management of benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this